Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$155.6MCash on Hand
19.1mo Cash Runway
Follow TRAX by emailGet an email when TRAX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TRAX, unsubscribe in one click. Privacy
📣 What TRAX Says Is Next
first half of 2027 · “We anticipate initiating Phase 2 development in vitiligo and one additional indication in the first half of 2027, and reporting top-line results from the celiac disease mucosal-healing cohort in the first quarter of 2027 and in eosinophilic esophagitis in the third quarter of 2027.” ANB033 (CD122 antagonist)”
Company press release, Nov 3, 2026 · SEC filing
in 2027 · “These data support our plans to progress ANB033 into late-stage development in 2027 in celiac disease as a potential treatment to prevent both acute symptoms and intestinal damage from gluten exposure despite general adherence to a gluten-free diet,” said Daniel Faga, president and chief executive officer.”
Company press release, Nov 3, 2026 · SEC filing
H1 2027 · “Anticipate initiating Phase 2 development of ANB033 in vitiligo and one additional indication in H1 2027”
Company press release, Nov 3, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 3, 2026 ·
Earnings Reported Q3 2026 net loss of $31.4 million ($0.88 per share), R&D of $23.8 million and G&A of $9.0 million. Cash was $155.6 million, pro forma $343 million after a $200 million private placement. Celiac Phase 1b mucosal-healing data expected Q1 2027. Form 8-K · SEC filing · Press release
Nov 3, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 26, 2026 ·
First Tracks Biotherapeutics, a spin-off from AnaptysBio, filed a registration statement. The filing discloses substitute options (6,641,885) and awards (1,514,446 and 1,109,394) issued from the AnaptysBio equity plan in the Spin-Off, plus December 31, 2025 investment maturity schedules. Form S-1 · SEC filing
Oct 20, 2026 ·
Financing Closed a private placement of 6,106,870 common shares on October 19, 2026, and entered a registration rights agreement requiring a resale registration statement to be filed within 30 days of closing. Form 8-K · SEC filing
Aug 13, 2026 ·
Earnings Prospectus supplement adds Q2 2026 10-Q: net loss of $33,374K for the quarter and $83,858K for six months, with cash and cash equivalents of $168,018K at June 30, 2026 and 35,730,843 shares outstanding as of August 7, 2026. Selling stockholders may resell up to 10,497,054 shares; the company receives no proceeds. Form 424B3 · SEC filing
Aug 12, 2026 ·
Earnings Reported Q2 2026 results: cash, cash equivalents and investments of $168.0 million at June 30, 2026, R&D expenses of $25.6 million for the quarter, and a net loss of $33.4 million or $0.95 per share. Reiterated cash runway into Q2 2028 and Fast Track designation for ANB033 in celiac disease. Form 8-K · SEC filing · Press release
Aug 12, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
TRAX holds $155.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $24.5M/quarter from operations,
an estimated runway of 19.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:6 · Low
Cash runway 19 months +8
S-1 registration (Oct 2026) +8
Raised after last reported balance sheet (Oct 2026) -10
Share count 42,017,901 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full TRAX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TRAX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.